| 厄洛替尼治疗EGFR突变的晚期非小细胞肺癌临床疗效分析 |
| 投稿时间：2016-11-02 修订日期：2016-11-11 点此下载全文 |
| 引用本文：郭丽丽,李明智,唐俊舫,武玮,陶虹,吴卫华,刘喆.厄洛替尼治疗EGFR突变的晚期非小细胞肺癌临床疗效分析[J].医学研究杂志,2017,46(3):138-140 |
| DOI：
10.11969/j.issn.1673-548X.2017.03.034 |
| 摘要点击次数: 1929 |
| 全文下载次数: 1237 |
|
|
| 中文摘要:目的 分析厄洛替尼治疗EGFR突变的晚期非小细胞肺癌临床疗效。方法 选取2012年12月~2015年12月在笔者医院住院治疗的97例晚期非小细胞肺癌（NSCLC）患者进行研究，所有患者经DNA直接测序法和ARMS方法对EGFR基因突变情况进行检查，并将其分为EGFR野生型组和突变型组，并比较厄洛替尼对两组患者的临床治疗效果。结果 EGFR突变型组患者近期临床治疗效果均显著高于野生型组（P<0.05）；突变型组患者中位生存期和总生存期等明显高于野生型组患者（P<0.05）；突变型组患者不良事件包括腹泻13例，皮疹7例，野生型组患者不良事件包括腹泻12例，皮疹17例，两组比较差异有统计学意义（P<0.05）。结论 厄洛替尼在治疗EGFR突变型晚期NSCLC患者方面其临床效果较好，且不良反应较轻，EGFR基因检测可为临床治疗提供参考依据。 |
| 中文关键词:厄洛替尼 EGFR突变 晚期非小细胞肺癌 临床效果 |
| |
| Analysis of Clinical Efficacy of Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer with EGFR Mutations |
|
|
| Abstract:Objective To analysis the clinical efficacy of erlotinib in the treatment of advanced non-small cell lung cancer with EGFR mutations. Methods Totally 97 patients with advanced non-small cell lung cancer with EGFR mutations treated in our hospital from Dec. 2012 to Dec. 2015 were studied, the EGFR gene mutation were detected by DNA direct sequencing method and ARMS method, and who were divided into wild group and mutant group, and the clinical effect were compared. Results The recent clinical effect in mutant group was significantly higher than that in wild group (P<0.05). The median survival time and total survival time in mutant group were significantly higher than that in wild group (P<0.05). In mutant group, 13 cases with diarrhea, 7 cases with skin rash; and in wild group, there are 12 cases with diarrhea, 17 cases with skin rash. The two groups had significant difference on adverse event (P<0.05). Conclusion It's good for clinical effect in treatment with erlotinib onpatients with EGFR mutated advanced NSCLC. |
| keywords:Eerlotinib EGFR mutation Advanced non-small cell lung cancer Clinical effect |
| 查看全文 查看/发表评论 下载PDF阅读器 |
